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INTRODUCTION
In  India,  there  are  around  20  million  carrier  cases  of 
β-thalassaemia  and around 8000-10,000 children are born every year 
with  β-thalassaemia major, Lokeshwar M.R. Shah N, Kanakia N. et.al 
2006.  The birth of a thalassaemia child places considerable health and 
economic strain not only on the affected child and his/her family but also 
on the community.
Since, thalassaemia is a severe and incurable disease, emphasis has 
to be shifted from the treatment of an affected child to the prevention of 
such births in future. Identifying carriers for  β- thalassaemia patients, 
thus plays an important role in preventing this, Verma IC et.al (1992).
β- thalassaemia trait presents with microcytic hypochromic blood 
picture similar to the picture of iron deficiency anemia and anemia of 
chronic diseases. The differentiation between these conditions becomes 
mandatory which usually  relies  on the measurement  of  serum ferritin, 
serum iron, total iron binding capacity and Hb A2 levels.
These  diagnostic  methods  are  costly  and  hence  constitute  a 
significant burden on public health economy particularly in developing 
countries  like  India.  This  made  the  way  for  developing  a  simple  and 
economic screening test for the detection of carriers of β- thalassemia.
In 1988 Mehta BC et al developed a simple cost effective screening 
test for the detection of cases of  β-thalassemia trait based on reduced 
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osmotic  fragility.  This  is  called NESTROFT (Naked Eye Single  Tube 
Red cell Osmotic Fragility Test). We have tried to assess the usefulness 
of this screening test in our paediatric cases presenting with anemia. 
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AIMS AND OBJECTIVES
This study was aimed :
1.  To  detect  cases  of  β-thalassemia  trait  in  paediatric  patients 
presenting with anaemia using NESTROFT as a screening tool.
2. To compare the various red cell indices and discriminant functions 
derived from them in identifying thalassemia trait.
3. To evaluate the peripheral smear findings with those cases.
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REVIEW OF LITERATURE
Thomas Cooley and Lee (1925) described a form of severe anemia 
that occurred in early life associated with splenomegaly and bonemarrow 
changes. George H.Whipple and William L. Brad ford (1932) coined the 
disease as thalassemia from “the sea” because early patients were all from 
regions surrounding the Meditteranean area.
Thomas Cooley and Lee loc.cit et al(1925) described the disease is 
the homozygous state of an autosomal gene for which an heterozygous 
state is  associated with much milder hematologic changes.  The severe 
homozygous  condition  to  be  known  as  thalassemia  major,  the 
heterozygous as thalassemia minor. 
Thalassemia  is  a  group  of  disorders,  each  resulting  from  an 
inherited  abnormality  of  globin  production  a  condition  collectively 
known as hemoglobinopathies. 
Thalassemias are classified into  βα and  by decreased or absent 
synthesis  of  βα and  globin chain respectively.  β -thalassemia is  the 
most common form of inherited hemoglobinopathy Model B et.al (1984).
Thalassemia is the most  common genetic disorder  worldwide.  It 
occurs with a particularly high frequency in a broad belt extending from 
the  Mediterranean basin through the Middle East, Indian sub continent, 
Burma,  South  East  Asia,  Melanesia  and  Islands  of  Pacific. 
Angastiniotis .M, Modell .B et al (1998).
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Approximately 3% of the world population carry  β-thalassemia 
gene.  In India frequencies between 3.5 and 14.9% have been reported 
ChattergiaJB et al (1976).
In  India,  β-thalassemia  has  a  high  frequency  in  certain 
communities  like  Punjabis,  who  have  migrated  from  West  Pakistan, 
Lohanas, Sindhis, Bengalis, Gujaratis, Bhanushalis, Gujaroti Khojas and 
Jains. Verma IC,et al loc cit(1992).
Indian   Academy  of  Paediatrics  has  reported  a  frequency  of 
thalassaemia trait of 3 – 18% in  Northern India and 1-3% or even less in 
the Southern part of India.
STRUCTURE OF HEMOGLOBIN
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Haemoglobin is a heterogenous mixture of protein consisting of the 
major  component  hemoglobin  A  and  the  minor  component  A2.  Each 
consists of two separate pairs of identical globin chains. In hemoglobin 
A, α   chain combine with β- chain )( 22 βα . In hemoglobin A2 α  chain 
combine with δ  chains ( )22 δα  and in Hemoglobin F α  chain combine 
with  γ chain  )( 22γα .  The primary structure of hemoglobin is  the four 
polypeptide chains attached to a haem molecule. Each chain is arranged 
in  a  series  of  eight  helical  segments  joined  by  short  non-helical 
segments,  is  referred  as  secondary  structure.  Each  heme  molecule  is 
enclosed in a pocket by the folds of the chain.
Fig1:  Structure of Haemoglobin
Globin gene Clusters:
11
The  α  genes cluster usually contains one functional  ε  gene and 
two α  gene ( )21 αα . The α  gene cluster also contains four pseudogenes 
121 ,, ψαψεεψ  and θ.
Both the genes are located in a region of homology approximately 
4  kb  long  and  interrupted  by  two  small  non-homologous  regions. 
Homologus regions are due to duplication of gene and non-homologus 
regions are due to DNA insertions into the non-coding regions around 
one  of  the  two  genes.  The  α gene  cluster  is  located  in  the  telomeric 
region of chromosome 16.
The β gene cluster is located in the short arm of chromosome 11, 
has γγ AandG  gene pairs and five functional genes βδε γγ andAG ,,, .
Different hemoglobins are produced during development and two 
globin gene switches take place. The embryonic  ε gene is found in the 
embryonic phase and produces hemoglobin - Hb Gower 1 ( )22ξε  and Hb 
Gower 2 ( )22 εα . The duplicated fetal γ  genes encode the globin chains 
γγ AandJ in the polypeptide chain, the fetal Hemoglobin contains 22 , γα  
chain and the fetal to adult hemoglobin switch occurs during the perinatal 
period.  Embryonic  hemoglobins  are  expressed  in  yolk  sac  and  fetal 
hemoglobins are produced in fetal liver. The embryonic and fetal switch 
occurs  during  6  and 10 weeks  of  gestation.  The  fetal  to  adult  switch 
12
occurs at about the time of birth, Karlsson. S et. al (1985) and Terrenato. 
L. et al (1981).
Fig-2 :Chromosomal Organization of the globin genes and their
            expression during development.
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MOLECULAR BIOLOGY OF GLOBIN GENE
Each globin gene is composed of three exons coding for functional 
domains of the hemoglobin and two intervening sequences (introns). The 
different  globin  gene  expression  is  controlled  by  the  action  of 
transcription factors and regulatory elements ie promoters, enhancers and 
silencers.
The promoters contain sequences that act as binding site for the 
transcription  factors  which  is  responsible  for  the  transcription  of  the 
structural genes. The relevant promoter sequences are TATA box located 
at the initiation site. AAT, CACU boxes located at approximately 70 and 
110 basepairs from the initiation site.
Enhancers  are  regulatory  elements  that  stimulate  transcription 
along with the promoters. Each of these regulatory sequences has binding 
site for the transcriptional activator and suppressor molecules.  
Where a gene is transcribed, mRNA is synthesized from the DNA 
strand by RNA polymerase. Initially, a large mRNA precursor is formed 
which  contains  both  introns  and  exons.  The  processing  of  mRNA 
involves modification at 5’ capping site and 3’ polyadenylation sites. The 
introns are subsequently eliminated and the exons are spliced together in 
nucleus.  At this  stage the mRNA moves to the cytoplasm to act  as  a 
template for the productions of globin chains. Transfer RNA transports 
aminoacids to the mRNA templates. 
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Thalassaemia syndromes result from a large number of molecular 
defects that alter expression of one or more of globin genes.
Molecular Pathology:
β-Thalassaemia is extremely heterogenous at the molecular level. 
More than 200 different mutations have been described. They fall  into 
two broad categories.
i. Deletion of the β globin gene
ii. Non – deletion mutation affects the transcription processing 
or translation of  β globin messenger. Point mutations are 
the most commonly involved one in β thalassaemia.
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Mutation:
β- thalassaemia mutations result in either a complete absence of 
β- globin chain ( 0β -thalassaemia) or a reduction of β-globin output (
+β -thalassaemia).
Fig-3:   The location of various classes of point mutations 
that    
             cause βthalassaemia with respect to important structural  
    element in the β-globin gene.
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Gene Deletion:
Gene deletion is generally rare in β-thalassaemia. One that  occurs 
at 619 basepair deletion at the end of the β gene, is relatively common, 
in the Sind and Punjab population of India and Pakistan. Thein Sl et. al 
(1984). In common, the deletion affects the promoter region or a part of 
the globin gene.
TRANSCRIPTIONAL MUTATIONS
Promoter Mutations:
They  reduce  the  binding  of  RNA  polymerase  and  the  rate  of 
mRNA transcription  to  20-30%,  resulting  in  reduced  β globin  chain 
output, Gonzales Redondo JM et. al (1989) Maragoudaki .E  et al  (1999).
5’ Untranslated Region mutations –  Is single base substitution 
and  minor deletion in 50- nucleotide region. Mutation at β globin gene, 
mRNA capsite (cap+1A → -C) shows thalassemia trait features, Wong C 
et al (1987). 
Mutations Affecting mRNA processing:
RNA processing consists of the removal of intervening sequences 
and the splicing of the coding regions to produce functional mRNA. This 
process  relies  on  sequences  present  at  intron  /  exon  boundaries.  The 
invariant dinucleotides  GT – at the 5’ and AG at the 3’ splice junctions 
and the flanking  sequences, are mutation site, Mount SM et al (1982). 
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Splice junction and consensus sequence mutation:
Mutations at  position 5q IVS-1 ( ), AGTGcG →→→  produce a 
consistent reduction of  β- globin synthesis leading to  oβ thalassaemia 
where  as  IVS  -1-6,  T → C  mutation,  is  quite  common  in  the 
Mediterranean  region  and  results  in  a  mild  thalassaemia  picture, 
Thamagnini G.P et al (1983).
Cryptic site mutation in introns and exons:
A number  of  nucleotide  substitution  involving  these  sequences, 
transform a cryptic site into a legitimate  one. Eg. IVS 1 AG→→110  
substitution,  GTIVS →→→1161  substitutions  results  in  +ββ ,o  
thalassaemia, Spritz  .R.A et al (1981) and Metherall JE et al  (1981).
Poly (A) and other 3’ untranslated Region mutants:
Polyadenylation  is  important  for  determining  the  stability  of 
mRNA, mutation at  the AAUA AA sequence affecting the translation 
leads to +β thalassaemia.
Mutation affecting mRNA translation:
A  large  group  of  mutations  alter  the  different  steps  of  mRNA 
translation. Initiation codon ATG mutation, nonsense codon TAA, TAG 
or TGA mutation and frame shift mutation affect the mRNA translation. 
The frame shift resulting from a single base deletion at codon 6 (-A) is 
relatively common in Mediterranean population where as - 4 nucleotide 
deletion at codon 41 and  42  common  in  Indian  population, Chang  JC 
et al (1983)and Kimurd A et al (1983).
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PATHOPHYSIOLOGY OF BETA- THALASSAEMIA
The basic defect  is  a reduced or absent  production of  β-globin 
chains with relative excess of  α -chains. This results in decrease in the 
hemoglobin production and an imbalance of globin chain synthesis. The 
former leads to reduction in mean cell hemoglobin (MCH) and mean cell 
volume (MCV). The latter has dramatic effects on the red cell precursors, 
resulting in  their  premature destruction in  the bone marrow and extra 
medullary  sites.  This  is  called  as  ineffective  erythropoiesis  and is  the 
hallmark of  β-thalassaemia,  Rachmilewitz  EA et al  (2001)and Finch 
CA et al (1970).
Fessas B et al., (1966) described the presence of inclusion bodies in 
erythroblasts  as  precipated  α  chains.  Oxidation  of  excess  α -chains 
results in the formation of hemichromes, which gives structural damage 
to red cell membrane. Excess chain precipitation in the red cell membrane 
causes  structural  and  functional  alterations  which  leads  to  changes  in 
deformability, stability and hydration of red cells, Rachmileritz EA et al 
loc cit (2001) Rachmileritz  EA et. al (1985). Schrier SL et. al (1989).
Besides  oxidation,  free  α -  chain  are  subjected  to  dehydration, 
resulting in the formation of denatured α - globin protein, heme and free 
iron. These degraded products damage the erythroid precursors and red 
cell  membranes.  Free iron,  via  the Fenton Reaction generates  reactive 
oxygen  species  which  causes  lipid  and  protein  peroxidation  with 
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subsequent damage to red cell membranes and intracellular organelles, 
Hebbel RP et al (1985) and Grinberg LN et al loc cit (1995).
These alterations of erythroid precursors result in an enhanced rate 
of apoptosis. Apoptosis contributes to ineffective erythropoiesis occurs at 
the polychromatophilic erythroblast stage, Yuan J et al (1993).
Finch CA et al loc cit (1970) stated that significant cases undergoes 
ineffective erythropoiesis  and anemia leads to increased erythropoietin 
production which causes marked erythroid hyperplasia which produces 
skeletal deformities and osteoporosis.   
A  significant  undergoes  ineffective  erythropoiesis  leads  to 
increased absorption of  iron resulting in iron over load.  Iron overload 
damages  myocardium,  endocrine  glands  either  directly  or  through 
hypothalamo pituitary axis. 
Removal of the abnormal RBC, by the reticuloendothelial elements 
of the spleen results in splenomegaly and hypersplenism.
Further  damage  of  RBC  membrane  causes  loss  of  normal 
asymmetric  distribution  and  increased  surface  exposure  of  the 
procoagulants, negatively charged phospholipids, phosphatidylserine and 
phosphatidyl ethanolamine.  The anionic phospholipids increase thrombin 
generation which leads to  activation of  platelets  and endothelial  cells, 
Borenstain  Benyashar et al(1993) and Helley D et al 1996.
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Fig 4:  Pathophysiology of β-thalassaemia
CLASSIFICATION OF BETA – THALASSAEMIA
21
Silent Carrier:  
These  patients  have  no  symptoms but  have  minimal  changes  in 
RBC indices. The mutation that causes the thalassaemia is very mild and 
represents +β  thalassaemias  ( +β / β).
β Thalassaemia Trait:                     
Patients have mild anaemia, abnormal RBC indices and abnormal 
hemoglobin electrophoresis with elevated HbA2, HbF or both.  Peripheral 
blood film usually shows marked hypochromia, microcytosis, target cells 
and  faint  basophilic  stippling.   The  production  of  β-  Chains  from 
abnormal  allele  varies  from  complete  absence  to  variable  degrees  of 
deficiency. ( +β / β) or ( 0β / β).
Thalassaemia Intermedia:
This  condition  is  usually  due  to  compound  heterozygous  state 
resulting in anaemia of intermediate severity.
β Thalassaemia associated with +β  chain structural variants:
The  most  significant  condition  in  this  group  of  thalassaemic 
syndromes is Hb S/ β thalassaemia which may vary in clinical severity 
from as mild as thalassaemia intermedia to as severe as β thalassaemia 
major.  When a  person inherits  one  sickle  cell  gene ( sβ )  and one  β 
thalassaemia gene the resulting disease is Hb S/ β thalassaemia disease. 
The severity of disease, clinical and laboratory findings of heterozygous 
Hb S/ β state varies  from asymptomatic to moderately severe disease. In 
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this condition the proportion of various hemoglobin are as follows HbS 
50 - 90%     HbA : 0 - 50%  Hb F:   2 - 30% and   Hb    A2  >  3.5%
Thalassaemia major ( ) ( ) ( )+++ ββββββ /;/:/ ooo  :
This condition is characterized by transfusion dependent anemia, 
massive splenomegaly, bone deformities, growth retardation and  peculiar 
facies in untreated individuals. HbF  levels  range  from  10  to 100%  and 
Hb A2 levels may be normal or increased upto 5 to 7%.  Peripheral smear 
shows microcytic hypochromic red cells, target cells, tear drop cells and 
nucleated RBC’s.
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THALASSAEMIA TRAIT
Clinical Features:
The  classic  heterozygous  carrier  of  β-  thalassaemia  is  usually 
asymptomatic.  The diagnosis is made through evaluation of a positive 
family history or during population screening, Gardileas C et al (1968), 
Pootralcul UP et al (1973). During pregnancy anemia is more severe than 
normal women, Cooley JR et al loccit (1984) White JM et al (1985). 
Malaria Hypothesis:
Maccanti  A  et.al  (1942)  observed  that  the  children  affected  by 
thalassaemia  came  from  malaria  endemic  areas.  Haldane  JBS  (1949) 
suggested  the  heterozygote  carrier  state  patients  have  a  selective 
advantage for survival where malaria is endemic.
The cellular mechanism responsible for the selective advantage of 
thalassaemia  heterozygotes  remain  incompletely  defined.  Erythrocytes 
containing high Hb F retard the growth and development of Plasmodium 
falciparam. Pasvol G et. al (1977).
Infants with  β-thalassaemia trait have a high Hb F in their first 
year  of  life  that  prevents  fatal  cerebral  malaria,  Weathirall  DJ  et.al 
(1981).
Using  modified  tissue  culture  Brockelman  et  al  (1987) 
demonstrated decreased parasitic multiplication in  β-thalassaemia trait 
red  cells.  They  theorized  that  Plasmodium  falciparam  resistance  was 
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consequence of the inability of the parasite to acquire nutrients through 
the digestion of hemoglobin in thalassaemic red cells.
Laboratory features:
1. Hemoglobin of value usually ranges from 9 to 11 gm/dl.
2. MCH values of 20 to 22 pg
3. MCV values of 50 to 70 fl, Miliard DP et al (1977).
4. Red cell count is elevated.
5. MCV is directly related to the degree of reduction in  β- globin 
production. MCHC is normal, Rund D et al (1992).
6. Red cell distribution width (RDW) is normal or increased.
7. Peripheral  smear  shows  microcytosis,  hypochromic, 
anisopoikilocytosis,  basophilic  stippling  and  reticulocytosis, 
Pootralcul P et al loc cit (1973). Weatherall DJ et al (1964).
8. Bone marrow study shows mild to moderate erythroid hyperplasia 
and  rare  red  cell  inclusions  and  mild  ineffective  erythropoiesis. 
Pearson HA et al (1960). Megaloblastic transformation as a result 
of  folic  acid  deficiency  and  it  occurs  occasionally,  during 
pregnancy.
9. Osmotic fragility in reduced.
10. Free erythrocyte protoporphyrin is normal or slightly increased .
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11. Serum Hb electrophoresis shows high HbA2 levels ranges from 3.5 
to 7 % , HbF is increased in half the patient ie 1-3% Mazza is et al , 
(1976) and Pootralcul P et al loc cit (1973). 
Inheritance of  β-thalassaemia:
                           O  + O+
                    β- β-
Burden of Thalassaemia in India:
Almost 25 million people in India are carriers of β - thalassaemia 
gene.  The prevalence of this gene varies from 1-17 with mean prevalence 
of 3.3%,  Verma IC et al loc cit (1992).  Over 9000 thalassaemia children 
are born in every year,  IAP text of  Paediatrics 5th edition 2006 these 
children  suffer  from  chronic  anemia  which  results  in  gross  facial 
deformity,  organomegaly  and poor  growth.   Only  10  –  15% of  these 
children receive optimal treatment,  Choudhry VP et al (1991). The cost 
of ideal treatment for each patient is 1 lakh per anum, Chaudhry VP et al 
loc cit (1991). 
Necessity of identifying β - thalassaemia trait
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The birth of a thalassaemia child places considerable health and 
economic strain not only on the affected child, but also to the community 
and nation.  Since it is a severe and incurable disease, emphasis must shift 
from treatment of the affected child to prevention of such birth in future, 
Raghavan K etal (1990).
Prevention of the β - thalassaemia major:
Advances in molecular diagnostic technique have made it possible 
to  diagnose  β -  thalassaemia  major  at  6  weeks  of  gestation.   Early 
antenatal  diagnosis  of  β -  thalassaemia  major  followed  by  medical 
termination  of  pregrancy  can  prevent  birth  of  children  with  β-
thalassaemia major. Prevention of birth of children with β-thalassaemia 
major  would  thus  spare  a  lot  of  distress,  effort  and  expenses  for  the 
families involved and for the society. The key requirement to prevent this 
disease is identification of couples at risk of giving birth to children with 
β- thalassaemia major. This can be done in two ways, Raghavan K et al 
loc cit (1990) and Manglani .M et al (1997).
(a) A population based screening for β thalassaemia trait: 
Mehta  BC  et  al  (2002)  stated  that   screening  of  the  general 
population would be the best way if resources were unlimited and the 
population manageable.  In a populous country such as India screening of 
communities  known to have high prevalence of  β-  thalassaemia trait 
would be more costeffective. While conventional counselling would be to 
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advise an individual  with  β -  thalassaemia trait  not  to marry another 
individual  with  β-  thalassaemia  trait.  The  study  found  “positive 
counselling” to be more acceptable and extremely useful.  Couples at risk 
of having children with β- thalassaemia major can be advised about the 
need for prenatal diagnosis at an early stage of pregnancy.
(b) Antenatal Screening:
All pregnant women attending antenatal clinic can be screened for 
β thalassaemia trait at the time of their first antenatal visit. The spouse 
of women found to be carriers after confirmatory tests should be tested 
for  β - thalassaemia trait to identify pregnancies  at risk of producing 
children  with  β thalassaemia  major.   Women  identified  to  have  β 
thalassaemia trait should avoid routine antenatal iron therapy, Mehta BC 
et al loc cit (2002). 
(c)Avoidance of excessive iron therapy:
Mild  to  moderate  degree  of  hypochromic  microcytic  anemia  is 
encountered in about 65 – 85 % of carriers of β- thalassaemia trait.  In 
the absence of definitive diagnosis, many of these patients receive oral or 
parenteral iron therapy.  This may go on intermittently or continuously 
for prolonged periods of time, as the anaemia persists. This iron therapy 
may result in iron overload, Mehta BC et al loc cit (2002).
d) The Need for a screening test for β thalassaemia trait:
28
The  diagnostic  test  for  β thalassaemia  trait  is  estimation  of 
hemoglobin  A2 by  electrophoresis  or  chromatography.  Both  these 
techniques  are  expensive  and  time  consuming  and  need  expensive 
equipment and laboratory expertise, Raghavan K etal loc cit (1990).
Cost effectiveness can be improved if definitive tests were to be 
performed only on samples with high chances of yielding positive results. 
The availability of an initial screening test which is inexpensive and easy 
to perform even under field conditions and can identify positive samples 
with  reasonable  sensitivity  and  specificity  would  be  technically  and 
financially attractive. 
Naked Eye single Tube Red cell Osmotic fragility test:
A simple test based on the lowered osmotic fragility of RBCS in 
thalassaemia has been applied in India by Mehta .BC et al (1988),  who 
first  used  the  term NESTROFT as  quoted  by  Verma IC et  al  loc  cit 
(1992).  The acronym NESTROFT stand for  Naked  Eye  Single  Tube 
Redcell  Osmotic Fragility  Test.  NESTROFT used  to  assess  osmotic 
fragility of red cells at a single concentration of buffered saline (0.36% in 
single tube) visually without a spectrophotometer. 
Procedure:
A stock  solution  of  10% buffered  saline  of  pH 7.4  is  prepared 
noted in (Appendix 1), from this,  1% buffered saline was prepared by 
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1:10 dilution with distilled water.  0.36% buffered saline was prepared 
from 1% buffered saline.
2 ml of 0.36% buffered saline was taken in one tube (10cm x 1 cm) 
and 2ml of distilled water was taken in another tube as control. A drop of 
well mixed EDTA blood was added to each of the tubes which were left 
undisturbed for 30 minutes at room temperature.
Interpretation:
After 30 minutes, the contents of both the tubes were shaken and 
the tubes held against  a  white paper on which a  thick black line was 
drawn.  The line would be clearly visible through the contents of the tube 
containing distilled water due to complete lysis.  If the line was similarly 
visible through the contents of the tube with buffered saline the test was 
considered negative,  where as  if  the  line was not  visible  the  test  was 
taken to be positive. 
The tubes were then left undisturbed for two hours.  The content of 
the  control  tube  shows  uniformly  pink,  the  tube  containing  buffered 
saline shows a sediment at the bottom and top part of saline is clear, the 
test is positive.  If the tube containing buffered saline is having similar to 
the control tube, it is taken as  negative.
Indication of positive NESTROFT:
A positive  NESTROFT indicates  that  all  the  red  cells  in  tested 
sample have not undergone complete lysis in 0.36% of buffered saline. 
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These unlysed red cells gives haziness of the contents of the tube and 
render the line on paper indistinct.  These red cells also sediment as a 
button at the bottom of test tube when it is left undisturbed for sometime. 
Thus a positive NESTROFT indicates decreased red cell osmotic fragility 
and increased resistance to osmotic fragility.
Utility of NESTROFT: 
Decreased osmotic fragility in  β-Thalassaemia trait, is indicated 
by a positive NESTROFT.  It is also positive in Iron deficiency anaemia, 
anaemia due to liver diseases, HbE disorder.
Confirmation of β-Thalassaemia Trait:
β-Thalassaemia trait can be confirmed by estimating the Hb A2 
level.   The  common  method  employed  for  estimating  Hb  A2 are 
Haemoglobin electrophoresis on cellulose acetate at alkaline pH.
Haemoglobin  A2 can  be  quantified  by  cellulose  acetate 
electrophoresis followed by elution and spectrometry but this is a labour 
intensive  technique  of  large  numbers  of  samples  require  testing. 
Quantification  of  haemoglobin  by  scanning  densitometry  is  not 
recommended as the precision is not good enough for detection of  β-
Thalassaemia trait, Clarke MG et al (2000) and Schmidt MR et al (1975) 
found that quantification of Hb A2 by densitometry produces   unreliable 
results   and  does  not  allow   differentiation  of β-Thalassaemia trait 
carriers from persons with normal levels of Hb A2. 
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Fig .5
the other hand quantitation of Hb A2 by elution from cellulose acetate 
membranes or by column chromatography yielded satisfactory results.
Fig – 6
Frequency  histogram  of  average  scanning  denstiometry  (with 
Helena)  values for  HbA2 from AA controls  and  β-Thalassaemia trait 
patients show an  overlap   which  means  that  this  method  cannot 
reliably   differentiate β-Thalassaemia trait from normal. 
ElutionValue (%): 
32
Schmidt MR et al loc cit (1975), frequency histogram obtained by 
elution from cellulose acetate membranes for HbA2 from AA controls and 
β-Thalassaemia trait  showed  good  separation  and  is  superior  to 
densitometric analysis.
At alkaline pH electrophoretic migration of HbC, HbE, HbA2 and 
HbO are similar HbS, HbD and HbG also comigrate, Clarke MG etal loc 
cit  (2000).  At acid pH (on citrate agar  or  agarose gel)  electophoretic 
separation of HbC from Hb E and HbO and HbS from HbD and HbG is 
accomplished.  It is not possible to differentiate HbE from HbO  and HbD 
from HbG   using  electrophoretic  methods.  This  is  usually  used  as  a 
supplement  to  cellulose  acetate  electrophoresis,  Bain  BJ  et  al  loc  cit 
(1998) and Cotton F et al (1999). 
Electrophoresis at acid pH is indicated in investigation of suspected 
high affinity haemoglobins even when electrophoresis at alkaline pH is 
normal, since certain high affinity haemoglobins have abnormal mobility 
in acid pH but normal mobility in alkaline pH .
Capillary Zone Electrophoresis (CZE)
This is a relatively new technique for the measurement of Hb A2 
and HbF,  Fredric Cotton et al  (1999) compared CZE with commonly 
used  quantitative  methods  like  cation  exchange  HPLC  and  anion 
exchange  chromatography  in  micro  columns  (MAEC)  CZE compared 
well with these methods and the advantage of CZE was that, presence of 
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HbS does not interfere with the estimation of HbA2, Shibabi  ZK et al 
(1999).   Measurement  of  Hb  A2 using  cation  –  exchange  HPLC  is 
complicated  in  individuals  with  HbS  because  Hb  A2 is  spuriously 
increased by the presence of HbS adducts. Which coelute with HbA2 in 
this system.  The different patterns obtained with CZE is shown in figure 
(A,B,C and D).
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Fig -7 Typical electrophenograms obtained by CZE,
In  the  above  mentioned  study  separation  of  Hb  fractions  was 
achieved in 6 mins. The hemolyzer marker, HbA2, HbS, HbF, and HbA 
displayed migration times of 4.59, 4.92, 4.99, 5.12, 5.27 min respectively.
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The imprecision by CZE technique ranged from 3% to 6% for Hb 
A2 and  HbF  at  physiological  and  pathological  concentrations.  The 
imprecision  was  always  <2%  for  migration  times.   The  CV  HbF 
quantification was 5 % for concentrations ranging from 1.8 to 18.9% The 
CV for Hb A2  was 3-6% for concentration ranging from 2.0 to 5.6% . 
Lenkin MA et al  (1997).
Microcytic hypochromic red cells with mild anisocytosis  also seen 
in the following conditions. 
1. Iron deficiency anemia
2. Anemia of chronic diseases
3. Sideroblastic anemia
4. β- thalassaemia major
Of these, Iron deficiency anemia, β thalassaemia trait and anemia
of  chronic  disease  account  for  more  than  80%  cases  of  microcytic 
hypochronic anemia.
 Iron deficiency anaemia:
The causes of iron deficiency anaemia are 
1. Decresed dietary intake
2. Impaired absorption
3. Increased requirement
4. Chronic blood loss
There is no regulated pathway for iron excretion, which is limited 
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to the 1-2 mg / day lost by shedding of mucosal and skin epithelial cells. 
The normal non – vegetarian diet contains 10 – 20 mg of iron mostly in 
the form of heme iron, about 20% of which is absorbed, (in content to 1 
to 2 % of non heme iron).  The total body iron content is normally 2 gm 
in women and upto 6 gm in men.  Approximately 80% of functional iron 
is bound in hemoglobin: rest 20% in myoglobin, iron binding enzymes 
and  cytochromes.  The  storage  pool  of  hemosiderin  and  ferritin  has 
approximately  15  to  20% of  total  body  iron.   Plasma  iron  bound  to 
transferrin  is  transported  to  the  marrow,  where  it  is  transferred  to 
developing red cells and is incorporated into hemoglobin.  Mature red 
cells are released into the circulation and after 120 days are ingested by 
macrophages in the reticuloendothelial system.  Hence iron is extracted 
from hemoglobin and returned to the plasma, completing the cycle.
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Fig – 8: Internal iron cycle
Clinical features of Iron deficiency anaemia:
Weakness,  lethargy,  koilonychia,  glossitis,  pharyngeal  webs, 
muscle dysfunction and gastritis, pica are other features.
Laboratory features:
Peripheral  smear  shows  microcytic  hypochromic  red  cells  with 
anisopoilkilocytosis  most  frequently  target  cells,  elliptocytes  and 
reticulocytosis,  White  blood cells  and platelets  are  usually  normal  but 
may be thrombocytosis seen in case of severe bleeding. 
Bone  marrow  shows  mild  to  moderate  increase  in  erythroid 
progenitors  predominantly  polychromatic  normoblasts  and 
micronormoblasts  and  disappearance  of  stainable  iron.  Granulopoietic 
cells and megakaryocytes are present in normal numbers and appearance.
Serum iron is decreased to less than 30  µg/dl. Total iron binding 
capacity is increased to 420 µq/dl. Transferrin saturation is decreased to 
less than 15%. Serum ferritin is decreased to less than 30 µg/dl.
Table–2: Iron studies in differentiating thalassaemia from iron defeciency
    anaemia.
Disease Serum
Iron
Serum
Ferritin
TIBC % of
saturation
Storage
Iron
BTT N or ↑ N to  ↑ N to↓ ↑ ↑
IDA N /↓ ↓ ↑ ↓ ↓
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Nathan and Oskis Hematology of infancy and childhood 2009.
Anaemia of chronic diseases:
It is the most common cause of anaemia in hospitalized patients. In 
chronic diseases, the red cell production is impaired leading to anaemia 
that  mimics iron deficiency anaemia the signs and symptoms of  these 
patient  depends upon the underlying disorder.
Laboratory findings:
Peripheral  smear  shows  normocytic  normochromic  red  cells,  in 
long  standing  cases  show  microcytic  hypochromic  blood  picture, 
reticulocytes counts are normal.
Iron  profile  shows  decreased  serum  iron,  decreased  total  iron 
binding  capacity,  low  transferrin  saturation  and  normal  or  increased 
serum ferritin.
RBC Indices and β thalassaemia trait,   Eldibany MM et. al (1999) 
and Telmissani OA et al (1992).
RBC indices were first introduced by Wintrobe et al (1940). These 
include MCV, MCH and MCHC. In βthalassaemia trait MCV is normal 
or rarely decreased. MCHC is also normal or decreased RDW is usually 
normal, Kanavakis E et al (1982).
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Table – 3: Red cell Indices in βthalassaemia and Iron deficiency   
      anaemia.
RDW
RBC
Count
MCV MCH MCHC
BTT Usually
Normal
N/or  ↑ ↓↓ ↓↓ ↓
IDA ↑ed ↓↓ ↓ ↓ ↓↓
DISCRIMINANT FUNCTIONS:
Mentzer index is an useful screening test, which is derived from 
MCV and RBC count if it is less than 13 considered as β-thalassaemia 
trait,  Mentzer  WC et al  loc cit  (1973) England and Fraser proposed a 
linear discriminant function (DF) derived from MCV, RBC count and Hb 
concentration,  positive  value  indicates  iron  deficiency  anemia  and 
negative value indicate  β- thalassaemia trait, England JM et al loc cit 
(1979)  .  Green  and  King  proposed  the  formula,  100
2
×
×
Hb
RDWMCV  with 
values  less  than  65  indicates  β-thalassaemia  trait.  Shine  and  Lal 
introduced the formula  
100
2 MCAMCV ×  with values less than 1530 was 
considered to β- thalassaemia trait, Shine I et al loc cit (1977).
Thomas  S  srivastava  A  et  al  (1996)  derived  the  formula  from 
MCH and RBC Count if it is > 3.80 it denotes iron defeciency anaemia, 
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< 3.80 denotes  β-thalassaemia trait.  Bessman JB et  al  loc cit  (1983) 
derived the RDW index from MCV, RDW and RBC count if the results 
are  >220  it  denotes  iron  deficiency  anaemia  if  <220  it  signifies  β-
thalassaemia trait.
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MATERIALS AND METHODS
In  my  study  i  have  included 100 patients  in  the age  group  of 
0-12yrs, all of whom presented with features and symptoms of anemia to 
the outpatient and inpatient ward, Department of Paediatrics, Tirunelveli 
Medical College Hospital, Tirunelveli during the period of August 2008 
to March 2009.
All  these  patients  were  subjected  to  basic  hematologic 
investigations and those who presented with Hb less than 11.5gm% and 
MCV of  less  than  80fl,  were  included in  the  study.  Peripheral  smear 
examination were done to exclude any hematological malignancy and β-
thalassaemia major.
Selected patients were subjected to the following investigations:
1. Complete  blood  hemogram  -  Total  RBC  count,  MCV,  MCH, 
MCHC and RDW were calculated in  all  selected patients  using 
automated cell counter Sysmax – K21,22 (Transasia biomedicals). 
2. Peripheral  smear  analysis  was  done  to  look  for  the  degree  of 
anisocytosis and poikilocytosis and  they were graded as mild (+), 
moderate  (++)  and  severe  (+++),  as  graded  in  US  standard 
reference. 
3. NESTROFT was  carried  out  in  these  cases  with  fresh  working 
solution. (Appendix No:1) Raghavan .K et. al (1998) Mehta BC et. 
al Ind. J. Hemat (1990)
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4. Discriminant functions like Mentzer’s index, England and Fraser 
index, Green and King Index, Shrivastava’s formula, Shine and Lal 
Index, RDW index were carried out with the data obtained from 
the cell counter.
Mentzer Index - Mentzer et al (1973).
MCV /RBC count
>13 Iron Deficiency Anemia
<13 β- thalassemia trait
England Fraser Index - England Fraser PM Lancet (1973).
MCV – 5 Hb – RBC – K. where K =8.4 
Positive value – Iron deficiency anemia. 
Negative value - β- thalassemia trait.
Green and King Index
MCV2 x RDW/Hb x 100
>65 Iron deficiency anemia
<65 β-thalassaemia trait
Srivastava’s formula -Thomas S. Srivastava A et.al (1996)
MCH / RBC
>3.80 – Iron deficiency anemia
<3.80 - β- thalassaemia trait
Shine and Lal Index - Shine I, Lal S.et al Lancet (1977)
MCV2 x MCH/100
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>1530 Iron deficiency anemia
<1530 β-thalassaemia trait
RDW Index  - Bessman JB, Gilmer Pri et.al (1983)
MCV x RDW/RBC count
>220 – Iron deficiency anemia
<220 - β- thalassaemia trait
5. NESTROFT  positive  samples  were  sent  to  Microbiological 
Laboratory,  Coimbatore  for  Hb electrophoresis  by  HPLC (D10-
BIORAD)  method.  Hb  A2  level  >3.5%  was  taken  as  the  gold 
standard to diagnose β-thalassemia trait.
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RESULTS
The  evaluated  patients  were  divided  into   two   groups  i.e  beta 
thalassaemia  trait  and  non  beta  thalassaemia  trait.   Beta  thalassaemia 
group includes positive NESTROFT and the standard reference values for 
various discriminant functions and peripheral smear showed microcytic 
hypochromic anemias.  Non beta thalassaemia trait group includes iron 
deficiency  anaemias,  anaemia  of  chronic  diseases  and  sideroblastic 
anaemias. 
Sensitivity,  specificity,  positive  predictive  value  and  negative 
predictive value of NESTROFT and the various discriminant functions 
were evaluated and their significant difference made out between them 
and tabulated.
Haemoglobin electrophoresis was done in all NESTROFT positive 
cases and three cases showed positive for beta thalassaemia trait.
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 Comparison of NESTROFT with other discrimiant functions:
β - thalasaemia trait was evaluated by Mentzers index and the same 
was screened by NESTROFT. 
Table – 1: Mentzer’s index and NESTROFT
Nestroft
Mentzer’s inex
BTT
Non 
BTT
Total
Sensitivit
y
Specificit
y
Positive 
predictiv
e value
Negative 
predicative 
value
Positive 14(a) 
(25%)
40(b) 
(75%)
54
Negativ
e
1(c) 
(2.1%
)
45(a) 
(97.9%
)
46 93.3% 52.9% 25.9% 97.8%
Total 15 85 100
    *BTT :- Beta Thalassaemia Trait. 
Sensitivity : ( ) 100×+caa =93.3%
Specificity : ( ) 100×+dbd =52.9%
Positive predictive value = ( ) 100×+baa =25.9%
Negative predictive value = ( ) 100×+dc
d
=97.8%
Table 1 shows sensitivity and specificity  and positive predictive 
value and negative predictive value of Mentzers index as calculated and 
the result  showed 93.3% of sensitivity and 52.9% of specificity which 
were statistically shows significant difference (p<0.01) postive predictive 
value and negative predictive value also showed statistically significant 
difference ( p<0.01).
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Table – 2: England Fraser index with NESTROFT
Nestroft
England transfer 
Index
BTT Non- 
BTT
Total
Sensitivit
y
Specificit
y
Positive 
predictiv
e value
Negative 
predicative 
value
Positive 50 
(92%
)
4 
(8%)
54
Negativ
e
9 
(20%
)
37 
(80%
)
46 84.7% 90.2% 92.6% 80.4%
Total 59 41 100
    *BTT :- Beta Thalassaemia Trait. 
Table  2  shows  the  percentage  of  sensitivity  and  specificity  of 
England Fraser  index were 84.7% and 90.2% which  were  statistically 
insignificant p>0.05 and similarly positive predictive value and negative 
predictive value were showed the insignificant difference of p>0.05.
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Table – 3: NESTROFT with Green and King index
Nestroft
Green and king 
index
BTT Non 
BTT
Total
Sensitivit
y
Specificit
y
Positive 
predictiv
e value
Negative 
predicative 
value
Positive 47 
(87%
)
7 
(13%
)
54
Negativ
e
4 
(8%)
42 
(92%
)
46 92.2% 85.7% 87.0% 91.3%
Total 51 449 100
     *BTT :- Beta Thalassaemia Trait. 
Table 3 shows sensitivity and specificity of Green and King index 
with NESTROFT positive cases were 92.2% and 85.7%. The difference 
for  the specificity and sensitivity was statistically insignificant  p>0.05. 
The positive and negative predictive value also did not differ significantly 
p>0.05.
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Table – 4: NESTROFT with Srivastava’s formula
Nestroft
Srivastavas 
BTT Non 
BTT
Total Sensitivit
y
Specificit
y
Positive 
predictiv
e value
Negative 
predicative 
value
Positive 33 
(62%)
21 
(38%)
54
Negativ
e
4 
(8.6%
)
42 
(91.4%
)
46 89.2% 66.7% 61.1% 91.3%
Total 37 53 100
     *BTT :- Beta Thalassaemia Trait. 
Table 4 shows the sensitivity of 89.2% and specificity of 66.7% of 
Srivastava’s formula which showed statistically significant difference of 
p<0.05.  The  positive  and  negative  predictive  value  also  showed  the 
significant difference of p<0.05.
Table – 5: NESTROFT with Shine and Lal index
Nestroft
Shine and car index 
BTT Non 
BTT
Total Sensitivit
y
Specificit
y
Positive 
predictiv
e value
Negative 
predicative 
value
Positive 53 
(98%
)
1 
(2%)
54
Negativ
e
30 
(65%
)
16 
(35%
)
46 63.8% 94.1% 98.2% 34.9%
Total 83 17 100
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     *BTT :- Beta Thalassaemia Trait. 
Table  5  shows the  sensitivity  of  63.8% specificity  of  94.1% of 
Shine and Lal index showed statistically significant difference of p<0.01. 
The positive predictive value and negative predictive value also showed 
the significant difference of p<0.01.
Table – 6: NESTROFT with RDW index 
 Nestrof
t
RDW index  
BTT Non 
BTT
Total Sensitivit
y
Specificit
y
Positive 
predictiv
e value
Negative 
predicative 
value
Positive 48 
(88%)
6 
(12%)
54
Negativ
e
3 
(6.5%
)
43 
(93.5%
)
46 94.1% 87.8% 88.9% 93.5%
Total 51 49 100
     *BTT :- Beta Thalassaemia Trait. 
Table 6 illustrates the sensitivity (94.1% ), the specificity (87.7%) 
positive predictive value ( 88.9%) negative predictive value (93.5%) of 
RDW index was statistically showed the insignificant difference p>0.05.
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Table – 7: COMPARISON OF THE VARIOUS 
DISCRIMINANT FUNCTIONS
Sl.No. Discriminant 
function 
Specificity Sensitivity Positive 
predictive 
value
Negative 
predictive 
value 
1 Mentzers 
Index 
52.9% 93.3% 25.9% 97.8%
2 England 
Fraser index
90.2% 84.7% 92.6% 80.4%
3 Green  and 
King index
85.75 92.2% 87.0% 91.3%
4 Srivastava’s 
formula 
66.7% 89.2% 61.1% 91.3%
5 Shine and Lal 
Index 
94.1% 63.8% 98.2% 34.9%
6 RDW index 87.8% 94.1% 88.9% 93.5%
 
Table 7 shows various discriminant functions Mentzer index, Shine 
& Lal index and Srivastava’s formula were statistically shows significant 
difference  and  were  ideal  for  screening  tools  to  identify  the  β 
-thalassemia  trait  cases.   From  the  above  results  the  association  of 
NESTROFT was evaluated with chi-square test (χ2) as below. 
Table 8: Association between NESTROFT with other indices
NESTROFT with Chi-square test (χ2) Significance
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Mentzer’s Index 9.21 P<0.01
Srivastava’s Formula 27.1 P<0.01
Shine and Lal Index 16.83 P<0.01
England Fraser Index 51.786 P<0.001
Green & King Index 57.910 P<0.001
RDW Index 64.180 P<0.001
Table 8 shows the analysis of chi-square test. The NESTROFT as a 
screening tool was positively associated with other indices. 
52
Table 9 : Comparison of red cell indices
Red cell 
indices
β-thalassemia 
trait cases
Non β- thalassemia
trait cases
Mean SD Mean SD 
MCV(fl) 59.6 4.2 72.8 7.3
MCH(pg) 19.1 1.9 24.1 5.4
RDW 14.3 0.8 15.3 2.5
RBC count 5.39 0.6 3.88 0.7
Hb level g/dl 10.6 0.6 8.3 1.9
 
In the present  study by employing the independent  t-test  it  was 
assessed  that  the  mean  MCV,  mean  MCH  were  lower  than  non  β-
thalassemia trait cases which is statistically significant with. P value of 
less than 0.001. 
Mean of the RDW values of the thalassemia trait cases in the study 
was 15.23.  Optimum cut off value of RDW to differentiate between B-
TT and IDA was found to be 15.23. The mean RDW of  β- thalassemia 
trait  was  significantly  lower  than  non  β-thalassemia  trait.   Since  the 
difference of mean 2 is statistically significant p <0.01
Mean RBC count is higher in  β- thalassemia trait as compared to 
non β -thalassemia trait cases. 
Table 10: Evaluation of peripheral smears.
Peripheral smears were evaluated for microcytosis, anisocytosis & 
hypochromias.
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β- thalassemia trait
Mild Moderate Severe 
Microcytosis 12 (22%) 40 (74%) 2 (4%)
Hypochromia 36 (66%) 17 (34%)
Anisocytosis 46 (85%) 9 (15%)
 
Table  10  shows,  peripheral  smears  of  β-thalassaemia  trait  cases 
were evaluated and showed mild to moderate microcytosis, hypochromic 
red cells with mild anisocytosis, few target cell seen in minimal cases 5% 
and very few cases 3% show occasional basophilic stipplings.
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DISCUSSION
This study was done to  evaluate the usefulness of NESTROFT 
along  with  various  other  RBC  indices  and  discriminant  function  in 
detecting cases of  beta thalassaemia trait and to differentiate them from 
non  beta  thalassaemia  trait  cases.  We  have  also  tried  to  evaluate  the 
peripheral smear findings with the RBC indices.
Regarding the usefulness of the NESTROFT as a screening test for 
the detection of beta thalassaemia trait our observation was almost similar 
to  that  of  Manglani  et  al  (1997)  who  have  screened  830  cases  from 
general population from various region of our country. The NESTROFT 
positive cases were confirmed with Hb electrophoresis.
The sensitivity, specificity, positive predictive value and negative 
predictive value were 64.2%, 94.4%, 97.6% and 35.3% respectively. We 
also  had  a  similar  observation  and  3  cases  were  positive  for  beta 
thalassaemia trait  by Hb electrophoresis.  Our positive predictive value 
was lower than that of the other similar studies due to the small size of 
the study group included. We have also tried to correlate the RBC indices 
and other discriminant function with other similar studies.
The  mean hemoglobin  value  of  our  study  group was  10.68m/dl 
which was lower than that of similar observation made by Madhan N et al 
(1994) with a hemoglobin of 11.6gm/dl, Das Gupta et al (1994) with a 
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mean hemoglobin of 11.2gm/dl, and Mohamed et al (1999) with 11.3gm/
dl. 
The  mean  red  blood  cell  count  values  of  our  study  group  was 
almost similar to that of the observation of Madhan N et al  loc cit (1994) 
with  5.67x106cells/cumm  and  Das  Gupta  et  al  loc  cit  (1994)  with 
5.6x106cells/cumm.
The mean MCV of our study group was 62.8fl. This was similar to 
the  observation  Madhan  N  et  al  (1994)  (or)  slightly  lower  than  the 
observation made by Mohamed et al (1999).
The mean RDW of our study was 14.3%. This was slightly lower 
than the values of Madhan N et al loc cit (1994) with 16.3% Das Gupta et 
al loc cit (1994) with 15%  of  Mohamed et al loc cit (1999) with 16.6%.
Comparing  the  sensitivity,  specificity,  positive  and  negative 
predictive value of various discriminant functions were found. Mentzers 
index and Shrivastava’s formula were the most useful screening test than 
the  others.  This  goes  in  hand with  the  observation  of  Manglani  et  al 
(1994) study, the sensitivity and specificity positive predictive value and 
negative predictive value of Mentzer’s Index were respectively 66.2%, 
82.8%, 89.5% and 44.3%. Ntaios et al found that sensitivity specificity, 
positive predictive value and negative predictive value were respectively 
59.78%,  98.3%,  99.11% and 44.02%.  In  our  present  study  sensitivity 
specificity, positive predictive value and negative predictive value were 
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respectively  73.3%, 59.9%,  25.9% and 97.8% which  compared to  the 
other studies and found that sensitivity is higher than other studies.
Manglani  et  al  loc  cit  (1994)  found  that  sensitivity  specificity, 
positive  predictive  value and negative predictive value of  Srivastava’s 
formula respectively, 55.6%, 79.7%, 85.0% and 36.1%.  In our present 
study  showed  sensitivity,  specificity,  positive  predictive  value  and 
negative  predictive  value  of  89.2%,  66.7%,  61.1%  and  91.3% which 
shows comparatively higher sensitivity value.
In  beta  thalassaemia  trait  cases  by  England  Fraser  (1979)  after 
evaluation  of  1500  peripheral  smears,  suggested  that  microcytic 
hypochromic red cells, significant target cells and basophilic stippling in 
RBCS.  In  the  present  study,  showed  mild  to  moderate  microcytic 
hypochromic  red  cells,  with  mild  anisocytosis  and  few  cases  (5%) 
showed target cells and very few cases (3%) showed basophilic stippling.
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SUMMARY AND CONCLUSION 
In this study we have analysed the usefulness of NESTROFT along 
with other discriminant function and peripheral smear evaluation to detect 
cases  of  beta  thalssaemia  trait  in  the  paediatric  cases  presenting  with 
anemia. 
A positive test of NESTROFT indicates lowered red cell osmotic 
fragilities which is suggestive of beta thalssaemia trait .  In our study on 
100 cases of anaemia, we had 54 cases with positive NESTROFT.  Those 
cases were further  subjected to hemoglobin electrophoresis in which we 
had 3 positive cases.   The NESTROFT positively was correlated with 
other discriminant function and we found Mentzers Index, Shine and Lal 
Index and Shrivastava’s  formula were ideal for screening cases  of beta 
thalssaemia trait as they showed stastiscally significant results.  The other 
discriminant function were of not much use in our study. 
Analysis of the various red cell indices has shown that the mean 
MCV value was 59.6fl in our cases much lower than that of non beta 
thalssaemia  trait  cases.   The  mean  hemoglobin  level  was  10.6  gm/dl 
much higher than the mean hemoglobin value in non  beta thalssaemia 
trait cases. 
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The mean RDW of beta thalssaemia trait was 14.3 whereas of the 
non beta thalssaemia trait was 15.3.
Evaluation of the peripheral smear showed very mild anisocytosis 
with microcytic hypochromic  red cells in our cases of beta thalssaemia 
trait. There was significant anisocytosis in cases of non beta thalssaemia 
trait.  The degree of  Poikilocytosis was very mild and even absent in 
most  of  our  cases  of  beta  thalssaemia  trait.  Moderate  degree  of 
polychromasia  was more common in case of beta thalssaemia trait than 
non beta thalssaemia trait. So we conclude a major screening programme 
including  various  red  cells  indices,  discriminant  function  and 
NESTORFT will be useful to detect cases of beta thalssaemia trait in the 
general population.  The present data will form a basic database for the 
forthcoming study. 
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PROFORMA
Name : Age/Sex:
Hospital No : Address  : Occupation:
Chief Complaints:
C/o 
• Breathlessness
• Palpitation
• Chest pain
• Cough.
• Fever
• Generalized weakness/fatigue
• Bleeding tendencies
• H/o Blood transfusion
General examination of:
• Pallor 
• Jaundice
• Cyanosis
• Clubbing
• Oedema
73
• Lymphadenopathy
Systemic Examination:
• Hepatomegaly
• Splenomegaly
• Respiratory system
• Cardiovascular system.
Investigation:
1. Complete Hemogram:
• Hb%
• TC
• DC
• RBC Count
• WBC Count
• PCV
• MCV
• MCH
• MCHC
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• RDW
2. Peripheral Smear Examination:
3. NESTROFT
4. Discriminant functions.
• Mentzer’s Index
• England Fraser Index
• Green and King Index
• Srivastava’s formula
• Shine and Lal Index
• RDW Index
5. Hemoglobin Electrophoresis.
6. Radiological examination – X – ray.
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